0.33 USD
▼-0.00-0.54%
盘后 0.35 0.00%
2026-09-16
市值
$49.40M
市盈率
—
EPS
-0.04
股息率
—
52 周区间
0.29 – 3.53
成交量
239.14K
Beta
2.20
目标价
1.50
52W 低 0.2952W 高 3.53
价格走势
公司简介
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb...